Easywell Biomedicals, Inc.
Research Easywell Biomedicals, Inc. (1799.TWO) on Bullrun: market cap TWD 3.52B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1799.TWO
- ExchangeTWO
- CountryTaiwan
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyTWD
- Market capTWD 3.52B
- Financial periodQ2 2026
- RevenueTWD 226.63M
- Net income-TWD 12.46M
- Free cash flowTWD 23.92M
- Gross margin43.3%
Valuation Snapshot
latest market cap is TWD 3.52B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 3.52B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 TWD.
About Easywell Biomedicals, Inc.
Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells generic pharmaceutical ingredients and products in America, China, and Taiwan. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for the treatment of breast cancer in PMS women; TLX-007 and TLX-004, which are anti-depressants; TLX-008 for the prevention of pneumocystis pneumonia; TLX-012 for the treatment of epilepsy; TLX-017 for the treatment of chronic angina;
ETFs that hold Easywell Biomedicals, Inc.
US-listed ETFs
Easywell Biomedicals, Inc. is held by 3 US-listed ETFs, going by the latest portfolios they filed with the SEC, most traded first:
| ETF | Weight | Fee |
|---|---|---|
| Dimensional Emerging Core Equity Market ETF (DFAE) | <0.01% | 0.29% |
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | <0.01% | 0.39% |
| Dimensional World ex U.S. Core Equity 2 ETF (DFAX) | <0.01% | 0.28% |
Portfolios as filed with the SEC on Form N-PORT, dated July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Easywell Biomedicals, Inc.'s market cap?
Easywell Biomedicals, Inc.'s market capitalization is TWD 3.52B.
What does Easywell Biomedicals, Inc. do?
Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells generic pharmaceutical ingredients and products in America, China, and Taiwan. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for the treatment of breast cancer in PMS women; TLX-007 and TLX-004, which are anti-depressants; TLX-008 for the prevention of pneumocystis pneumonia; TLX-012 for the treatment of epilepsy; TLX-017 for the treatment of chronic angina; and TLX-011 for the treatment of inflammatory lesions of rosacea.